QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
QQQ   280.53 (-0.41%)
AAPL   140.94 (-1.38%)
MSFT   244.37 (-0.31%)
META   113.93 (-0.17%)
GOOGL   94.94 (-2.10%)
AMZN   88.46 (+0.24%)
TSLA   174.04 (-3.21%)
NVDA   161.20 (+0.83%)
NIO   12.58 (-4.98%)
BABA   88.33 (-3.41%)
AMD   70.14 (-0.19%)
T   19.30 (+0.68%)
MU   53.82 (+0.26%)
CGC   3.24 (-10.25%)
F   13.10 (-1.36%)
GE   85.00 (-0.33%)
DIS   92.15 (-0.15%)
AMC   6.05 (-10.37%)
PYPL   74.42 (+3.03%)
PFE   50.24 (+1.07%)
NFLX   308.42 (+0.94%)
NASDAQ:VSTM

Verastem - VSTM Stock Forecast, Price & News

$0.40
+0.01 (+2.56%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.39
$0.41
50-Day Range
$0.30
$0.93
52-Week Range
$0.29
$2.56
Volume
486,611 shs
Average Volume
1.87 million shs
Market Capitalization
$84.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Verastem MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,150.0% Upside
$5.00 Price Target
Short Interest
Healthy
1.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$8,463 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.39) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

281st out of 1,027 stocks

Pharmaceutical Preparations Industry

121st out of 503 stocks

VSTM stock logo

About Verastem (NASDAQ:VSTM) Stock

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

VSTM Stock News Headlines

Verastem (NASDAQ:VSTM) Now Covered by Analysts at StockNews.com
Verastem: Moving Forward (NASDAQ:VSTM) - Seeking Alpha
Verastem (NASDAQ: VSTM)
Verastem (VSTM) Investor Presentation - Slideshow
Verastem: Q2 Earnings Snapshot
Is Verastem (NASDAQ:VSTM) Using Too Much Debt?
See More Headlines
Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

VSTM Company Calendar

Last Earnings
11/04/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VSTM
CUSIP
92337C10
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+1,150.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-71,200,000.00
Net Margins
-2,007.44%
Pretax Margin
-2,339.54%

Debt

Sales & Book Value

Annual Sales
$2.05 million
Book Value
$0.48 per share

Miscellaneous

Free Float
203,368,000
Market Cap
$84.04 million
Optionable
Optionable
Beta
0.63

Key Executives

  • Mr. Brian M. Stuglik BPHARM (Age 63)
    R.Ph., RPh, CEO & Director
    Comp: $1.04M
  • Mr. Daniel W. Paterson (Age 61)
    COO & Pres
    Comp: $710.39k
  • Mr. Richard H. Aldrich M.B.A. (Age 68)
    Mba, Founder and Consultant
  • Dr. Robert A. Weinberg Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta Ph.D.
    Co-Founder
  • Dr. Michelle Dipp M.D. (Age 46)
    Ph.D., Co-Founder
  • Mr. Daniel Calkins (Age 35)
    Interim Principal Accounting Officer & Financial Officer
  • Dr. Jonathan Pachter Ph.D. (Age 64)
    Chief Scientific Officer
  • Ms. Erin S. Cox
    Sr. Director of Investor Relations & Corp. Communications
  • Mr. Sean C. Flynn (Age 48)
    VP, Gen. Counsel & Sec.













VSTM Stock - Frequently Asked Questions

Should I buy or sell Verastem stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings
or view top-rated stocks.

What is Verastem's stock price forecast for 2023?

6 Wall Street analysts have issued 12 month target prices for Verastem's stock. Their VSTM share price forecasts range from $3.00 to $6.00. On average, they anticipate the company's share price to reach $5.00 in the next year. This suggests a possible upside of 1,146.0% from the stock's current price.
View analysts price targets for VSTM
or view top-rated stocks among Wall Street analysts.

How have VSTM shares performed in 2022?

Verastem's stock was trading at $2.05 at the beginning of the year. Since then, VSTM shares have decreased by 80.4% and is now trading at $0.4013.
View the best growth stocks for 2022 here
.

Are investors shorting Verastem?

Verastem saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 2,280,000 shares, a decrease of 42.7% from the October 31st total of 3,980,000 shares. Based on an average daily volume of 1,560,000 shares, the short-interest ratio is presently 1.5 days.
View Verastem's Short Interest
.

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our VSTM earnings forecast
.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.05. Verastem had a negative net margin of 2,007.44% and a negative trailing twelve-month return on equity of 106.08%.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Who are Verastem's major shareholders?

Verastem's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.05%), Eagle Asset Management Inc. (2.86%), BlackRock Inc. (2.03%), Two Sigma Advisers LP (0.45%), UBS Oconnor LLC (0.42%) and Renaissance Technologies LLC (0.36%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich.
View institutional ownership trends
.

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $0.40.

How much money does Verastem make?

Verastem (NASDAQ:VSTM) has a market capitalization of $84.31 million and generates $2.05 million in revenue each year. The biopharmaceutical company earns $-71,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for the company is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at bsullivan@verastem.com.

This page (NASDAQ:VSTM) was last updated on 12/7/2022 by MarketBeat.com Staff